Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

Erin Kelly is likely going to forget her eight-year-old daughter Evie’s name before her little girl finishes high school.

Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

A Harvard team reverses dementia in mice with a metal supplement, after showing that its deficiency drives the disease ...

Years of investigation by scientists at Harvard has revealed that lithium is deeply involved in Alzheimer’s disease, a ...

A new Alzheimer’s drug, lecanemab, may slow disease progression and offer patients up to four extra years of stable health.

Lithium could help treat cases of Alzheimer’s disease, a Harvard study suggests. People with the neurodegenerative condition ...